Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2017
- Source ID
- 10.1016/j.bbmt.2017.02.017
Entities
People
- Christa L. Meyer
- David J Vanness
- Ellen M. Denzen
- Jaime M. Preussler
- Kristen C. Edsall
- Lih-wen Mau
- Linda J. Burns
- Navneet S Majhail
- Stephanie H. Farnia
- Wael Saber
Organizations
- AABB
- Amgen
- Astellas Pharma (United States)
- BioMarin Pharmaceutical
- Biogen
- Blue Cross Blue Shield Association
- Celgene
- CellGenix (Germany)
- Children’s Leukemia Research Association
- Eisai (South Korea)
- Elevance Health, Inc.
- Genzyme
- Health Resources and Services Administration
- HistoGenetics (United States)
- John F. Kennedy School of Government
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- Milliman
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Oncology Nursing Society
- Osiris Therapeutics
- Otsuka (United States)
- Pfizer
- Roche (United States)
- Shire (United States)
- Sigma-Tau Pharmaceuticals (United States)
- StemCyte
- Terumo BCT (United States)
- United States Public Health Service